GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Underperform
ALKS
down 49.35 %

Alkermes, Inc. (ALKS) downgraded to Underperform by BofA/Merrill

Posted on: Friday,  Apr 26, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Alkermes, Inc. (NASDAQ: ALKS) on 04/26/2013, when the stock price was $30.98. Since
then, Alkermes, Inc. has gained 97.45% as of 01/21/2016's recent price of $61.17.
If you would have followed this BofA/Merrill's recommendation on ALKS, you would have lost 49.35% of your investment in 1000 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

BofA/Merrill
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/26/2013 8:25 AM Sell
None
30.98
as of 12/13/2013
1 Week up  0.87 %
1 Month down  -5.19 %
3 Months down  -15.22 %
1 YTD down  -27.50 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/1/2013 8:25 AM Hold
None
21.76

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy